ccr8

CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.

AZ084 is a potent, selective, allosteric, and orally active CCR8 antagonist (Ki: 0.9 nM) with potential to treat asthma.

LMD-009 is a non-peptide, selective CCR8 agonist that mediates chemotaxis, inositol phosphate accumulation, and calcium release, with an EC50 of 11–87 nM.

ML604086 suppresses CCL1 mediated chemotaxis and enhances intracellular Ca2 concentrations. ML604086 is a selective inhibitor of CCR8. It also inhibiting CCL1 binding to CCR8 on circulating T-cells.

R243 is CCR8 signaling and chemotaxis inhibitor.

ZK 756326 is a selective, non-peptide CCR8 chemokine receptor agonist (IC50: 1.8 μM, in human; 2.6 μM, in mouse). Displays no activity at CCR4/5 and CXCR3/4 and shows higher 28-fold selectivity over 26 other GPCRs (less selective at α2A and 5-HT receptors). Induces chemotaxis and inhibits Env-mediated (HIV) cell-cell fusion.

CCR8 agonist1 (Compound 2) is an activator of CCR8 and is applicable in studies related to autoimmune diseases.

CCR8 antagonist 3 (compound 2), a potent inhibitor of CCR8, exhibits an IC 50 value of 0.062 µM and demonstrates stability in human microsomes [1].

Anti-CCR8 Antibody (10A11) is a humanized IgG1 monoclonal antibody targeting CCR8.

SB-649701 is a potent antagonist of the human CCR8 receptor, exhibiting a pIC50 value of 7.7, and is utilized in asthma research [1].

Imzokitug is a humanized IgG1κ monoclonal antibody targeting CKR-L1, with its corresponding isotype control being HumanIgG1kappa, Isotype Control.

LMD-584 serves as an agonist for CCR8 and is an analogue of LMD-009.

LMD-A, also known as CCR8 antagonist LMD-A, is a CCR8 antagonist.

AZ760 is a CCR8 antagonist that demonstrates excellent potency, good lipophilicity, and a high free fraction in blood, but exhibits unacceptable hERG inhibition [1].

S-531011 is a human IgG1 monoclonal antibody that targets CCR8. It reduces tumor-infiltrating CCR8+ Tregs and exhibits antitumor activity in CT26.WT and EMT6 tumor-bearing mouse models. S-531011 is useful for cancer immunotherapy research. The recommended isotype control is HumanIgG1kappa, Isotype Control.

LM-108 is a monoclonal antibody that targets CCR8. It selectively eliminates tumor-infiltrating regulatory T cells (Treg) and is applicable to gastric cancer research.

Tagmokitug is a humanized IgG1κ monoclonal antibody inhibitor targeting CCR8. It exhibits anti-tumor activity and is applicable in cancer immunotherapy research, including studies on breast cancer, colon cancer, and lung cancer.

Cafelkibart is a chimeric IgG1κ monoclonal antibody targeting CCR8, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.

Lanerkitug is a humanized IgG1λ2 antibody that targets CCR8, with HumanIgG1lambda2, Isotype Control serving as its corresponding isotype control.

Denikitug is a chimeric antibody of the IgG1κ type that targets CCR8, with its corresponding isotype control being HumanIgG1kappa, Isotype Control.

Azirkitug is a humanized IgG1κ antibody targeting CCR8, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.

CHS-114 (SRF-114) is a fully human IgG1 antibody targeting the (CCR8) receptor. It shows potential for research in head and neck squamous cell carcinoma (HNSCC). The isotype control for CHS-114 can be referred to as HumanIgG1kappa, Isotype Control.

Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody that targets the human C-C motif chemokine receptor 8 (CCR8). It holds potential for research in various solid tumors and hematological malignancies.